University of Messina   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Messina Italy (1548)

Organization Overview

First Clinical Trial
2003
NCT00355953
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Antonio Persico | Azienda Ospedaliera Universitaria G Martino, Messina, Italy. | Azienda Ospedali Riuniti Papardo-Piemonte, Messina | Department of Neuroscience, University of Messina | Hematology, Azienda Ospedali Riuniti Papardo-Piemonte, Messina, Italy. | Nephrology Division, Medical School, University of Messina, Italy | Univeristy of Messina | University of Messina | University of Messina, Italy | University of Messina, ITALY

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 2)

Bone Diseases, Metabolic (Phase 3)

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Crohn Disease (Phase 3)

Endometrial Hyperplasia (Phase 2)

Foot Ulcer (Phase 4)

Glomerulonephritis (Phase 3)

Glomerulonephritis, Membranous (Phase 3)

Hyperplasia (Phase 2)

Inflammatory Bowel Diseases (Phase 3)

Intestinal Diseases (Phase 3)

Lymphoma (Phase 3)

Lymphoma, Follicular (Phase 3)

Metabolic Syndrome (Phase 3)

Muscular Dystrophies (Phase 1)

Muscular Dystrophy, Duchenne (Phase 1)

Osteoporosis (Phase 3)

Syndrome (Phase 3)

Ulcer (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 29
  • # of Trial APIs: 41